Wall Street Researcher
PRESSURE BIOSCIENCES INC
PBIO OTCQB
STRONG FY 2021
BREAKOUT TERRITORY
BUYING OPPORTUNITY !
Planet Micro Vegas - PBIO Fact Sheet -
Speaker Details Wed 11;30 AM
Strong Market Demand Fuels Company's Decision to Access
Early Revenue Generating Opportunities for UST Processing of
High Quality Nanoemulsions of Oil-Based Active Ingredients
for Multiple Markets Ahead of Q4 2022 Commercialization -
Company Expects Several Executed Contracts During Q2 2022
These shares have spiked to the
upside on STRONG Financials . We feel that the 200 day M/A of $2.41 could be
tested to the upside soon. Average daily volume is 31,127 shares for the
same 200 day period .
A superior management team is
driving these shares higher discovering new uses for their
medical device and achieveing record sales for March 2022 - Ultra Shear Tech Platform
We feel that a
BUYING OPPORTUNITY is now at hand
. All
serious investors must place these shares on their
BUY LIST and watch carefully for an UPSIDE
BREAKOUT - Our Target $3.50
Research Report - Pressure BioSciences - PBIO
OTC
WATCH THIS MOST RECENT INVESTOR VIDEO WITH
PRESSURE BIOSCIENCE CEO RIC SCHUMACHER
MOMENTUM PLAY -
ARCHER INVESTMENT BUYS PBIO
This is a bullet point summary describing reasons to own
PBIO
- PBI has been working for
several years with companies in multiple markets that
need high quality nanoemulsions
- PBI’s collaborators range
from start-ups to multi-billion dollar, multi-national,
very well-known companies
- PBI’s commercialization plan
is to set up two Tolling Sites (San Fran and Boston) and
have them available for “fee-for-service” contracts by
Q4 2022
- PBI has been asked by
potential customers in multiple application areas
(nutraceutical, health and beauty, agrochem, etc.) if
there was a way to access the UST platform before Q4
2022
- To offer early access to
UST, PBI needs the BaroShear equipment. The four
BaroShear MAX systems needed for the Tolling Sites are
obviously not available or the tolling would begin
earlier.
- In the press release, PBI
states that it has now finished the build of three
BaroShear MINIs, and expects to finish the build of both
a BaroShear K45 and MAX shortly. These five machines
can be used for early access.
- The need for high quality,
water soluble, long-term stable nanoemulsions is
tremendous in multiple industries: pharma,
nutraceuticals, health and beauty, agrochem, food and
beverage, and more.
- High quality nanoemulsions
make the oil-based active ingredient (e.g., CBD,
prednisone, retinol, astaxanthin, Vitamin D3, etc.)
significantly more bioavailable, because the
nanoemulsion is highly water soluble
- There are many pretenders
out in the market. PBI’s nanoemulsions processed by UST
are real, high quality, long-term stable. To support
this statement, PBI has partnered with the College of
Food, Agriculture, and Environmental Science at The Ohio
State University and they have a BaroShear MAX and they
are using it and publishing on it. Great Credibility.
- A lot of the Quality of a
nanoemulsion is based on the formulation and stabilizers
used. PBI mentioned in the release that their
stabilizers are custom-made, plant-based, non-GMO,
non-allergenic, organic/green/natural.
- Many other companies use
stabilizers that are not custom-made for each active
ingredient but they use a “one-size-fits-all” approach;
some use synthetic chemicals; some are not plant-based,
etc.
- UST-processed nanoemulsions
have also been shown to magnify the taste, small,
silkiness of the processed material…and with food, to
not lose its nutritious value
- IMPORTANT: UST allows the
user to “dial-in” the size of the oil droplets desired.
Sometimes a nanoemulsion of 50nm may be wanted,
sometimes it might be 100nm, and sometimes even 200nm.
Very unique to UST, the user can pre-determine the range
of the size desired and then process to that range. PBI
believes that no other method can duplicate this
critical capability
- Microorganisms are destroyed
by UST – primarily from the use of the Company’s
patented nano-gap valve. So UST can result in a
clean-labelled product - that is a product that does not
contain anti-microbial chemical agents.
- PBI stated in the release
that it is working with many different companies and
that they expect to be announcing several contracts for
the Early Access Program in the current Q2 2022.
Pressure BioSciences Announces Early Access Program for UST
Nanoemulsion Processing
Strong Market Demand Fuels Company's Decision to Access
Early Revenue Generating Opportunities for UST
Processing of High Quality Nanoemulsions of Oil-Based
Active Ingredients for Multiple Markets Ahead of Q4 2022
Commercialization - Company Expects Several Executed
Contracts During Q2 2022
SOUTH EASTON, MA / ACCESSWIRE / April 27, 2022 / Pressure
BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"),
a leader in the development and sale of broadly
enabling, pressure-based instruments, consumables, and
specialty testing services to the worldwide
biotechnology, biotherapeutics, nutraceuticals,
cosmetics, agriculture, and food & beverage industries,
today announced the initiation of an Early Access
Program (effective July 1, 2022) for the use of its
revolutionary Ultra Shear Technology™ ("UST™") platform
for the processing of oil-based active ingredients into
highly stable, water soluble, long-term stable
nanoemulsions.
In
September 2021, and reinforced several times since, the
Company announced plans for the commercialization of its
revolutionary UST platform. Under this plan,
commercialization activities are to begin with the
opening of two fee-for-service, GMP-compliant tolling
centers in the 2022 fourth quarter. These centers are to
be located in the Boston and San Francisco areas. Good
progress continues to be made in this effort.
Importantly however, PBI has been experiencing more
immediate demand for UST-processed nanoemulsions.
Although the UST platform systems and laboratory space
required for the tolling sites will not be available
until later in 2022, the Company currently has three
working benchtop, small-capacity systems (BaroShear
MINI) and expects to soon finish the manufacture of both
a mid-capacity BaroShear K45 and a large-capacity
BaroShear MAX (capable of very large production runs).
Propelled by this very welcomed demand to use the UST
platform, and aware that such use could help to
accelerate the trajectory of commercial proof of
principle, production engagement, and conversion into
long term processing relationships with a diverse group
of prospective partners in the nutraceutical, health and
beauty, agrochem, and food/beverage industries, PBI has
decided to open up a program to allow early access to
the UST processing system.
Mr.
John B. Hollister, Director of Sales and Marketing at
PBI, addressed the burgeoning demand for access to PBI's
UST platform for processing valuable oil/water
emulsion-based products in multiple major markets: "We
have announced our plans to have commercial
toll-production UST-processing capacity operational on
the East and West coasts of the USA by Q4 2022. Since
announcing this, we have worked closely with a number of
companies on formulating some of their products. As a
result, the demand to serve initial contracts for
pilot-scale production of nanoemulsions in
nutraceuticals, cosmetics, health and beauty care, and
agrochemical markets has become particularly intense and
is growing. We anticipate the announcement of at least
two significant relationships and contracts within these
sectors during Q2 2022, for which early small-batch
production capacity can be pivotal to accelerating the
commercialization phase to follow."
Dr.
Alexander Lazarev, Chief Science Officer at PBI, said:
"UST, by design, is a scalable and precisely controlled
process that allows us to "dial in" and routinely
deliver sub100 nm nanoemulsions of desired
characteristics. Resulting oil droplets become smaller
than the wavelength of visible light, at which point the
previously cloudy/opaque emulsions become transparent
nanoemulsions. More importantly, oil-soluble bioactive
molecules are now in nano-droplets so small that they
become more readily absorbable and bioavailable. Taste
and smell characteristics are similarly magnified, while
textures are ultimately transformed into silkiness and
lower viscosity. Most microorganisms are also destroyed
in the process, yielding room-temperature stability
against spoilage without a need for preservatives.
Moreover, nanoemulsions are easily sterilized by
filtration, which makes them ideal media for
pharmaceutical drug delivery. These nanoemulsions
exhibit remarkable stability against physical separation
when prepared using our minimal custom formulations of
plant-based, non-GMO, non-allergenic, organic/green
natural stabilizers designed for clean label products."
PBI's President and CEO, Mr. Richard T. Schumacher,
expanded: "Our early demonstrations of UST processing
have astonished our prospective partners, including
prednisone for pharmaceuticals; retinol for cosmetics;
neem oil for agrochem; and astaxanthin, curcumin, krill
oil, algae oil, and CBD for nutraceuticals. Retained
samples were subjected to stability testing, and such
testing has helped confirm that stability was completely
maintained with full clarity at the key two-year
milestone. We have demonstrated our ability to deliver
these results at production scales from our BaroShear
Mini to our K45 and MAX systems. Our first MAX system
has been operational at the renowned Pilot Test Lab of
The Ohio State University since January, and we
anticipate that our consortium partnership with Ohio
State will shortly launch into close working
relationships on UST with diverse major global companies
in the liquid food and beverage industry. Our plans
remain on track to complete the development of four
additional MAX systems and begin offering UST tolling
services in East/West coast facilities by Q4 2022.
Finally, we now have seven issued UST patents and
believe that more will be awarded to us over the coming
months."
Mr.
Schumacher concluded: "The PBI Team has been
extraordinarily driven and focused, which has been
instrumental in moving the UST platform from a critical
R&D project to the point where we are just months away
from proving the commercial viability, scalability, and
the incredible product quality generated by the UST
platform. Progress for PBI has been exciting as we have
laid the foundations for UST over the past several years
and we remain driven by our belief that without a doubt
the best is yet to come."
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in
the development and sale of innovative, broadly
enabling, pressure-based solutions for the worldwide
life sciences and other industries. Our products are
based on the unique properties of both constant (i.e.,
static) and alternating (i.e., pressure cycling
technology, or PCT) hydrostatic pressure. PCT is a
patented enabling technology platform that uses
alternating cycles of hydrostatic pressure between
ambient and ultra-high levels to control bio-molecular
interactions safely and reproducibly (e.g., cell lysis,
biomolecule extraction). Our primary focus is in the
development of PCT-based products for biomarker and
target discovery, drug design and development,
biotherapeutics characterization and quality control,
soil & plant biology, forensics, and counter-bioterror
applications. Additionally, major new market
opportunities have emerged in the use of our
pressure-based technologies in the following areas: (1)
the use of our recently acquired, patented technology
from BaroFold, Inc. (the "BaroFold" technology) to allow
entry into the bio-pharma contract services sector, and
(2) the use of our recently-patented, scalable,
high-efficiency, pressure-based Ultra Shear Technology
("UST") platform to (i) create stable nanoemulsions of
otherwise immiscible fluids (e.g., oils and water) and
to (ii) prepare higher quality, homogenized, extended
shelf-life or room temperature stable low-acid liquid
foods that cannot be effectively preserved using
existing non-thermal technologies.
Forward Looking Statements
This press release contains forward-looking statements.
These statements relate to future events or our future
financial performance and involve known and unknown
risks, uncertainties and other factors that may cause
our or our industry's actual results, levels of
activity, performance, or achievements to be materially
different from any future results, levels of activity,
performance or achievements expressed, implied, or
inferred by these forward-looking statements. In some
cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "could,"
"would," "expects," "plans," "intends," "anticipates,"
"believes," estimates," "predicts," "projects,"
"potential" or "continue" or the negative of such terms
and other comparable terminology. These statements are
only predictions based on our current expectations and
projections about future events. You should not place
undue reliance on these statements. In evaluating these
statements, you should specifically consider various
factors. Actual events or results may differ materially.
These and other factors may cause our actual results to
differ materially from any forward-looking statement.
These risks, uncertainties, and other factors include,
but are not limited to, the risks and uncertainties
discussed under the heading "Risk Factors" in the
Company's Annual Report on Form 10-K for the year ended
December 31, 2021, and other reports filed by the
Company from time to time with the SEC. The Company
undertakes no obligation to update any of the
information included in this release, except as
otherwise required by law.
Pressure BioSciences Leveraging Strong FY2021 Operational
and Financial Successes, Worldwide Customer Base,
Substantial IP Estate, and Three Powerful Technology
Platforms to Accelerate Strategic Company Transformation in
2022
Q4 and FY2021 Total Revenue Increased 91% and 64%
Respectfully Over Same Periods in 2020;
PCT, BaroFold, and PBI Agrochem Groups Scored Important
Gains in 2021;
UST Platform Achieved Critical 2021 Goals - Discussions
Ongoing with Key Leaders in Multiple Markets
Investor Conference Call Scheduled for Tuesday April 5
at 4:30 PM ET
SOUTH EASTON, MA / ACCESSWIRE / April 5, 2022 / Pressure
BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"),
a leader in the development and sale of broadly
enabling, pressure-based instruments, consumables, and
innovative services to the worldwide biotherapeutics,
nutraceuticals, cosmetics, agrochem, food & beverage,
and other industries, today announced financial results
for the fourth quarter and fiscal year ended December
31, 2021, provided a business update, and offered
guidance on the Company's strategic changes and growth
acceleration planned for FY 2022.
Over the past 15 years, PBI has acquired a wealth of
knowledge and experience in the use of pressure to
create remarkable results in a variety of
commercially-attractive areas using the Company's three
enabling technology platforms: Pressure Cycling
Technology ("PCT"), BaroFold™, and Ultra Shear
Technology™ ("UST™").
Jeffrey N. Peterson, Chairman of the PBI Board, set the
stage for PBI's exciting future: "The PCT and BaroFold
technologies have provided important early opportunities
for commercial traction, as PBI forged scientific
understanding and acceptance for its high-pressure
platforms. Building on multiple peer-reviewed opinion
leader scientific articles and presentations,
accelerating instrument installations, and expanding
paid research projects, these platforms are expected to
generate important sales growth in 2022 and beyond. In
addition, we believe the UST platform is opening up a
new, game-changing growth trajectory with its promise
for revolutionizing massive global markets from
pharmaceuticals, nutraceuticals, cosmetics, agrochem,
food/beverage processing, and more."
Richard T. Schumacher, President and CEO of PBI,
continued the thought: "As we evaluated the prospective
commercial successes for our technologies and products,
UST singularly stood out. After extensive development
efforts and due diligence, we came to understand that
the proprietary UST platform is a disruptive technology
with revenue potential that we believe can be
transformative for PBI and the major markets it will
serve. We have consequently focused the majority of the
PBI Team's 2021 efforts on UST development and on the
commercial introduction and acceleration for UST in
2022."
Mr.
John Hollister joined the PBI Team as Director of
Marketing and Sales in 2020. He came to PBI with broad
experience in leading commercialization of major
products in large companies like SmithKline (now GSK)
and Amgen, as well as in the start-up world for the
previous 17 years. His diverse experience in
successfully developing and leading marketing programs
(including initial product commercialization) with both
large and modest budgets will be pivotal for PBI, as he
leads our UST commercialization program. He is already
driving the planning and execution of critical
partnering and initial commercialization strategies in
order to build rapid and robust customer adoption and to
accelerate growth in 2022.
Mr.
Hollister said: "The amazing PBI Team has spent years
becoming experts in how to safely capture and utilize
pressure to improve existing methods in research and
pharmaceutical manufacturing. With the 2022
commercialization of UST, PBI will introduce to the
world the full potential of what pressure can do in a
variety of large and growing markets. The coming months
will be a very exciting time for PBI, our customers, and
for the users of their UST-processed products."
Financial Results: Q4 2021 vs. Q4 2020
-
Total revenue for Q4 2021 was $315,199 compared to
$164,702 for the same period in 2020, a 91%
increase. This increase was primarily due to our
double-digit growth in products and services.
-
Sales of instruments increased to $115,784 in Q4
2021 compared to $0 in Q4 2020.
-
Consumable sales were $82,680 for Q4 2021 compared
to $48,651 for the same period in 2020, a 70%
increase.
-
Operating loss for Q4 2021 was $1,221,148 compared
to $1,041,293 for the same period in 2020, primarily
due to increases in general and administrative
expense.
-
Loss per common share - basic & diluted - decreased
to $(0.48) for Q4 2021 from $(1.19) for Q4 2020.
Financial Results: FY2021 vs. FY2020
-
Total revenue for FY 2021 was $2,002,365 compared to
$1,220,591 for FY2020, a 64% increase. This increase
was primarily due to our growth in products and
services.
-
Sales of instruments increased to $1,105,268 for FY
2021 compared to $568,457 for FY 2020, an increase
of 94%
-
Consumable sales were $274,108 for the year ended
December 31, 2021 compared to $204,889 for the same
period in 2020, an increase of $69,219 or 34%.
-
Operating loss for FY 2021 was $4,185,147 compared
to $4,585,787 for FY 2020. This decrease was
primarily due to increases in total revenue.
-
Loss per common share - basic and diluted -
decreased to $(3.42) for FY2021 from $(5.32) for the
2020 fiscal year.
Operational & Technical Highlights (2021/2022)
-
Solid progress reported on FY 2022 key goals.
-
Ohio State installs/commissions BaroShear MAX UST
processing equipment at renowned Food Pilot Plant.
-
UST processing achieves 18-month stability of CBD
oil nanoemulsion.
-
Five UST patents awarded, including two for critical
nanogap valve.
-
Strong demand observed for our BaroFold protein
refolding platform specialty testing services.
-
UST successfully transforms Neem Oil into a novel
highly potent nanoemulsion for effective agrochem
use.
-
UST demo and manufacturing sites (Fall 2022) named:
Boston, MA and Mountain View, CA.
-
PBI establishes wholly-owned PBI Agrochem
subsidiary.
-
UST platform successfully processes one of the
world's most potent antioxidants: Astaxanthin.
-
PBI and Ohio State University announce partnership
in the formation of a food industry consortium to
advance commercialization of the UST platform.
Earnings Call and Business Update
The
Company will hold an Earnings Conference Call and
Business Update at 4:30 PM ET on Tuesday, April 5, 2022.
To attend this teleconference via telephone, Dial-in:
(888) 506-0062 (North America), (973) 528-0011
(International). Verbal Passcode: 648452 or say Pressure
BioSciences Fourth Quarter and Fiscal Year 2021
Financial Call. Replay Number (877) 481-4010; (919)
882-2331 (International). Replay Passcode: 45153.
Teleconference Replay Available for 30 days.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in
the development and sale of innovative, broadly
enabling, pressure-based solutions for the worldwide
life sciences and other industries. Our products are
based on the unique properties of both constant (i.e.,
static) and alternating (i.e., pressure cycling
technology, or PCT) hydrostatic pressure. PCT is a
patented enabling technology platform that uses
alternating cycles of hydrostatic pressure between
ambient and ultra-high levels to control bio-molecular
interactions safely and reproducibly (e.g., cell lysis,
biomolecule extraction). Our primary focus is in the
development of PCT-based products for biomarker and
target discovery, drug design and development,
biotherapeutics characterization and quality control,
soil & plant biology, forensics, and counter-bioterror
applications. Additionally, major new market
opportunities have emerged in the use of our
pressure-based technologies in the following areas: (1)
the use of our recently acquired, patented technology
from BaroFold, Inc. (the "BaroFold" technology) to allow
entry into the bio-pharma contract services sector, and
(2) the use of our recently-patented, scalable,
high-efficiency, pressure-based Ultra Shear Technology
("UST") platform to (i) create stable nanoemulsions of
otherwise immiscible fluids (e.g., oils and water) and
to (ii) prepare higher quality, homogenized, extended
shelf-life or room temperature stable low-acid liquid
foods that cannot be effectively preserved using
existing non-thermal technologies.
Forward Looking Statements
This press release contains forward-looking statements.
These statements relate to future events or our future
financial performance and involve known and unknown
risks, uncertainties and other factors that may cause
our or our industry's actual results, levels of
activity, performance, or achievements to be materially
different from any future results, levels of activity,
performance or achievements expressed, implied, or
inferred by these forward-looking statements. In some
cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "could,"
"would," "expects," "plans," "intends," "anticipates,"
"believes," estimates," "predicts," "projects,"
"potential" or "continue" or the negative of such terms
and other comparable terminology. These statements are
only predictions based on our current expectations and
projections about future events. You should not place
undue reliance on these statements. In evaluating these
statements, you should specifically consider various
factors. Actual events or results may differ materially.
These and other factors may cause our actual results to
differ materially from any forward-looking statement.
These risks, uncertainties, and other factors include,
but are not limited to, the risks and uncertainties
discussed under the heading "Risk Factors" in the
Company's Annual Report on Form 10-K for the year ended
December 31, 2021, and other reports filed by the
Company from time to time with the SEC. The Company
undertakes no obligation to update any of the
information included in this release, except as
otherwise required by law.
For more information about PBI and this press release,
please click on the following website link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.
PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
|
|
|
|
|
|
|
|
|
For the Three Months Ended |
|
|
For the Year Ended |
|
|
|
December 31, |
|
|
December 31, |
|
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
Products, services, other
|
|
$ |
315,199 |
|
|
$ |
164,702 |
|
|
$ |
2,002,365 |
|
|
$ |
1,220,591 |
|
Total revenue
|
|
|
315,199 |
|
|
|
164,702 |
|
|
|
2,002,365 |
|
|
|
1220,591 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of products and services
|
|
|
171,278 |
|
|
|
25,813 |
|
|
|
942,383 |
|
|
|
582,854 |
|
Research and development
|
|
|
262,437 |
|
|
|
335,696 |
|
|
|
1,101,509 |
|
|
|
1,143,420 |
|
Selling and marketing
|
|
|
72,519 |
|
|
|
125,197 |
|
|
|
324,728 |
|
|
|
649,783 |
|
General and administrative
|
|
|
1,030,113 |
|
|
|
719,289 |
|
|
|
3,818,892 |
|
|
|
3,430,321 |
|
Total operating costs and expenses
|
|
|
1,536,347 |
|
|
|
1,205,995 |
|
|
|
6,187,512 |
|
|
|
5,806,378 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss
|
|
|
(1,221,148 |
) |
|
|
(1,041,293 |
) |
|
|
(4,185,147 |
) |
|
|
(4,585,787 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (expense) income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense, net
|
|
|
(2,925,935 |
) |
|
|
(2,842,964 |
) |
|
|
(14,450,241 |
) |
|
|
(8,344,236 |
) |
Unrealized (loss) gain on investment in
equity securities
|
|
|
(52,574 |
) |
|
|
13,635 |
|
|
|
(457,025 |
) |
|
|
500,358 |
|
Gain/(loss) on extinguishment of
liabilities
|
|
|
320,042 |
|
|
|
(333,506 |
) |
|
|
(1,061,073 |
) |
|
|
(3,575,878 |
) |
Total other expense
|
|
|
(2,658,467 |
) |
|
|
(3,162,835 |
) |
|
|
(15,968,339 |
) |
|
|
(11,419,756 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
(3,879,615 |
) |
|
|
(4,204,128 |
) |
|
|
(20,153,486 |
) |
|
|
(16,005,543 |
) |
Deemed dividend on beneficial conversion
feature
|
|
|
- |
|
|
|
(61,180 |
) |
|
|
(873,798 |
) |
|
|
(61,180 |
) |
Preferred stock dividends
|
|
|
(418,640 |
) |
|
|
(399,461 |
) |
|
|
(1,658,175 |
) |
|
|
(1,517,987 |
) |
Net loss attributable to common
shareholders
|
|
$ |
(4,298,255 |
) |
|
$ |
(4,664,769 |
) |
|
$ |
(22,685,459 |
) |
|
$ |
(17,584,710 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common share - basic and
diluted
|
|
$ |
(0.48 |
) |
|
$ |
(1.19 |
) |
|
$ |
(3.42 |
) |
|
$ |
(5.32 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common stock shares
outstanding used in the basic and
diluted net loss per share calculation
|
|
|
8,921,086 |
|
|
|
3,907,046 |
|
|
|
6,636,523 |
|
|
|
3,304,187 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
|
|
|
|
|
|
|
|
|
December 31, 2021 |
|
|
December 31, 2020 |
|
ASSETS
|
|
|
|
|
|
|
CURRENT ASSETS
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$ |
132,311 |
|
|
$ |
18,540 |
|
Accounts receivable
|
|
|
154,746 |
|
|
|
131,228 |
|
Inventories, net of $342,496 reserve at
December 31, 2021 and December 31, 2020
|
|
|
1,147,554 |
|
|
|
592,767 |
|
Prepaid expenses and other current
assets
|
|
|
422,617 |
|
|
|
314,936 |
|
Total current assets
|
|
|
1,857,228 |
|
|
|
1,057,471 |
|
Investment in equity securities
|
|
|
59,976 |
|
|
|
517,001 |
|
Property and equipment, net
|
|
|
115,846 |
|
|
|
16,490 |
|
Right of use asset leases
|
|
|
395,565 |
|
|
|
221,432 |
|
Intangible assets, net
|
|
|
403,846 |
|
|
|
490,385 |
|
TOTAL ASSETS
|
|
$ |
2,832,461 |
|
|
$ |
2,302,779 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' DEFICIT
|
|
|
|
|
|
|
|
|
CURRENT LIABILITIES
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$ |
527,924 |
|
|
$ |
771,945 |
|
Accrued employee compensation
|
|
|
117,680 |
|
|
|
417,578 |
|
Accrued professional fees and other
|
|
|
1,955,672 |
|
|
|
2,037,806 |
|
Other current liabilities
|
|
|
7,757,217 |
|
|
|
6,330,722 |
|
Deferred revenue
|
|
|
37,124 |
|
|
|
47,328 |
|
Convertible debt, net of unamortized
discounts of $1,536,649 and $3,948,167,
respectively
|
|
|
12,839,813 |
|
|
|
7,545,670 |
|
|
|
|
|
|
|
|
|
|
Other debt
|
|
|
1,256,840 |
|
|
|
1,135,469 |
|
Operating lease liability
|
|
|
132,996 |
|
|
|
65,193 |
|
Other related party debt
|
|
|
- |
|
|
|
166,000 |
|
Total current liabilities
|
|
|
24,625,266 |
|
|
|
18,517,711 |
|
LONG TERM LIABILITIES
|
|
|
|
|
|
|
|
|
Long term debt
|
|
|
150,000 |
|
|
|
527,039 |
|
Operating lease liability - long term
|
|
|
262,569 |
|
|
|
156,239 |
|
Deferred revenue
|
|
|
3,587 |
|
|
|
19,382 |
|
TOTAL LIABILITIES
|
|
|
25,041,422 |
|
|
|
19,220,371 |
|
STOCKHOLDERS??? DEFICIT
|
|
|
|
|
|
|
|
|
Series D Convertible Preferred Stock,
$.01 par value; 850 shares authorized;
300 shares issued and outstanding on
December 31, 2021 and 2020, respectively
(Liquidation value of $300,000)
|
|
|
3 |
|
|
|
3 |
|
Series G Convertible Preferred Stock,
$.01 par value; 240,000 shares
authorized; 80,570 shares issued and
outstanding on December 31, 2021 and
2020, respectively
|
|
|
806 |
|
|
|
806 |
|
Series H Convertible Preferred Stock,
$.01 par value; 10,000 shares
authorized; 10,000 shares issued and
outstanding on December 31, 2021 and
2020, respectively
|
|
|
100 |
|
|
|
100 |
|
Series H2 Convertible Preferred Stock,
$.01 par value; 21 shares authorized; 21
shares issued and outstanding on
December 31, 2021 and 2020, respectively
|
|
|
- |
|
|
|
- |
|
Series J Convertible Preferred Stock,
$.01 par value; 6,250 shares authorized;
3,458 shares issued and outstanding on
December 31, 2021 and 2020, respectively
|
|
|
35 |
|
|
|
35 |
|
Series K Convertible Preferred Stock,
$.01 par value; 15,000 shares
authorized; 6,880 shares issued and
outstanding on December 31, 2021 and
2020, respectively
|
|
|
68 |
|
|
|
68 |
|
Series AA Convertible Preferred Stock,
$.01 par value; 10,000 shares
authorized; 8,649 and 8,043 shares
issued and outstanding on December 31,
2021 and 2020, respectively
|
|
|
87 |
|
|
|
81 |
|
Convertible Preferred Stock
|
|
|
|
|
|
|
|
|
Common stock, $.01 par value;
100,000,000 shares authorized; 9,120,526
and 4,168,324 shares issued and
outstanding on December 31, 2021 and
2020 respectively
|
|
|
91,206 |
|
|
|
41,683 |
|
Warrants to acquire common stock
|
|
|
31,715,154 |
|
|
|
29,192,471 |
|
Additional paid-in capital
|
|
|
64,261,048 |
|
|
|
50,312,968 |
|
Accumulated deficit
|
|
|
(118,277,468 |
) |
|
|
(96,465,807 |
) |
Total stockholders' deficit
|
|
|
(22,208,961 |
) |
|
|
(16,917,592 |
) |
TOTAL LIABILITIES AND STOCKHOLDERS'
DEFICIT
|
|
$ |
2,832,461 |
|
|
$ |
2,302,779 |
|
|
|
|
|
|
|
|
|
|
Neither PSN or WSR nor its owners, members, officers,
directors, partners, consultants, nor anyone involved in the
publication of this website, is a registered investment
adviser or broker-dealer or associated person with a
registered investment adviser or broker-dealer and none of
the foregoing make any recommendation that the purchase or
sale of securities of any company profiled in the PSN or WSR
website is suitable or advisable for any person or that an
investment or transaction in such securities will be
profitable. The information contained in the PSN or WSR
website is not intended to be, and shall not constitute, an
offer to sell nor the solicitation of any offer to buy any
security. The information presented in the PSN or WSR
website is provided for informational purposes only and is
not to be treated as advice or a recommendation to make any
specific investment. Please consult with an independent
investment adviser and qualified investment professional
before making an investment decision. Writer charges PBIO a fee
of $950 per month . All Reports are
reviewed for accuracy and concur that
any conclusions made are reasonable expectations. The
term Buy List referring to a Watch List and not a
recommendation to buy . Each individual has their own risk
level and should know their risk level and act accordingly
|